Details for Patent: 10,005,761
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 10,005,761 protect, and when does it expire?
Patent 10,005,761 protects BRAFTOVI and MEKTOVI and is included in two NDAs.
This patent has seventy-four patent family members in forty-nine countries.
Summary for Patent: 10,005,761
Title: | Compounds and compositions as protein kinase inhibitors |
Abstract: | The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. |
Inventor(s): | Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA) |
Assignee: | Array BioPharma Inc. (Boulder, CO) |
Application Number: | 15/070,905 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,005,761
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF MELANOMA | See Plans and Pricing | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF MELANOMA | See Plans and Pricing | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY | See Plans and Pricing | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST | See Plans and Pricing | ||||
Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,005,761
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 077975 | See Plans and Pricing | |||
Australia | 2010286569 | See Plans and Pricing | |||
Brazil | 112012004453 | See Plans and Pricing | |||
Canada | 2771775 | See Plans and Pricing | |||
Chile | 2012000340 | See Plans and Pricing | |||
China | 102725283 | See Plans and Pricing | |||
China | 103896921 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |